Brii Biosciences files arbitration demand against Vir over elebsiran manufacturing transfer

Vir Biotechnology

Vir Biotechnology

VIR

0.00
  • Brii Biosciences filed arbitration demand on April 16, 2026 against Vir Biotechnology at US-based JAMS over disputes tied to elebsiran manufacturing transfer.
  • Claims allege Vir breached 2018 collaboration agreement plus December 19, 2024 Sixth Letter Agreement covering transfer of drug product formulation manufacturing responsibility to Brii.
  • Relief sought includes order for specific performance to transfer elebsiran manufacturing to Brii or its contractors.
  • Damages claim seeks recovery for losses to date, including alleged lost profits plus amounts invested in collaboration.
  • Brii said it cannot yet predict outcome or quantify financial impact because proceedings are at an early stage.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260416-12108330), on April 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.